Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
Public ClinicalTrials.gov record NCT04768296. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Open-label, Single-arm Study of Berzosertib (M6620) in Combination With Topotecan in Participants With Relapsed Platinum-resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to assess efficacy, safety, tolerability and pharmacokinetics (PK) of Berzosertib in combination with Topotecan in participants with relapsed, platinum-resistant small-cell lung cancer (SCLC). This study will be conducted in two parts: safety run-in part and main part. The safety run-in part will be conducted in Japan.
Study identification
- NCT ID
- NCT04768296
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 76 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 29, 2021 (Actual)
- Primary completion
- Jul 21, 2023 (Actual)
- Completion
- Jul 21, 2023 (Actual)
- Last update posted
- Sep 26, 2024
2021 – 2023
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Medical Foundation | Santa Rosa | California | 95403 | — |
| St Joseph Heritage Healthcare | Santa Rosa | California | 95403 | — |
| Cotton-O'Neil Clinical Research Center, Hematology and Oncology | Topeka | Kansas | 66606 | — |
| National Cancer Institute | Bethesda | Maryland | 20892 | — |
| Cancer & Hematology Centers of Western Michigan | Grand Rapids | Michigan | 49546 | — |
| MidAmerica Cancer Care | Kansas City | Missouri | 64114 | — |
| NJ Center for Cancer Research | Brick | New Jersey | 08724 | — |
| Southeastern Medical Oncology Center | Goldsboro | North Carolina | 27534 | — |
| FirstHealth of the Carolinas, Inc. | Pinehurst | North Carolina | 28374 | — |
| Summa Health | Akron | Ohio | 44304 | — |
| Toledo Clinic | Toledo | Ohio | 43623 | — |
| Millennium Physicians Association, LLP | Houston | Texas | 77090 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04768296, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 26, 2024 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04768296 live on ClinicalTrials.gov.